Table 2.
Pharmacokinetic parameters of melphalan after intravenous administration of 100 mg m−2 over 1 h with co-administration of aprepitant (125 mg) or placebo
| Aprepitant (n = 10) | Placebo (n = 20) | Mann–Whitney test | Difference of means (95% CI) | |||
|---|---|---|---|---|---|---|
| Mean | SD | Mean | SD | P-value | ||
| t1/2 (h) | 1.28 | 0.19 | 1.30 | 0.18 | 0.9825 | −0.022 (−0.166, 0.123) |
| tmax (h) | 0.04 | 0.03 | 0.03 | 0.03 | 0.3811 | 0.008 (−0.14, 0.029) |
| Cmax (ng ml−1) | 3431 | 608 | 3269 | 660 | 0.5234 | 163 (−348, 673) |
| AUC (ng ml−1 h) | 5711 | 1342 | 6213 | 1724 | 0.5526 | −501 (−1779, 777) |
| AUCextrapolated (%) | 1.84 | 1.94 | 2.21 | 2.00 | 0.5526 | − |
| Vz (l m−2) | 33.3 | 6.8 | 32.1 | 8.2 | 0.5824 | 1.24 (−4.96, 7.43) |
| CL (l h−1 m−2) | 18.2 | 3.5 | 17.3 | 4.7 | 0.5526 | 0.92 (−2.53, 4.37) |
| MRT (h) | 1.57 | 0.24 | 1.75 | 0.25 | 0.0903 | −0.174 (−0.371, 0.024) |
| Vss (l m−2) | 28.3 | 5.1 | 29.5 | 6.6 | 0.6760 | −1.28 (−6.18, 3.64) |
t1/2 terminal elimination half-life, tmax time where the maximum plasma concentration after the end of infusion was observed, Cmax maximum plasma concentration, AUC area under the plasma concentration time curve from zero to infinity, AUCextrapolated, percentage of AUC due to extrapolation from the last measured concentration to infinity, Vz volume of distribution based on the terminal phase, CL total body clearance, MRT mean residence time, Vss, volume of distribution at steady-state.